P377

P377 - Mycophenolate mofetil in Lupus Nephritis – effective and safe over at least 10 years, a single centre experience.

Dr Hannah Beckwith1,2, Dr Beatriz R. Cubillo3, Dr Camilla Pillay2, Dr Andrew Porter2, Dr Tabitha Turner-Stokes1,2, Dr Hannah Wilson1,2, Dr Megan Griffith2, Dr Jeremy Levy2, Dr Tom Cairns2, Prof Liz Lightstone1,2

1 Imperial College London, London, United Kingdom, 2 Imperial College Lupus Centre, Imperial College Healthcare NHS Trust, London, United Kingdom

Objectives:

To review long-term efficacy and safety of treatment of lupus nephritis (LN) with mycophenolate mofetil (MMF), to address a gap in available data and to help inform treatment decisions.

Methods:

We have used MMF for the treatment of LN since 1999 and undertook a retrospective case-note review of all patients whose treatment included MMF. We compared those who received Cyclophosphamide (CyP) induction followed by MMF maintenance (CyP/MMF) with those who received MMF for both induction and maintenance (MMF/MMF).

Results:

From a database of 496 patients with biopsy-proven LN, 100 patients who started MMF ≥10 years ago were identified.

The patients were predominantly female (79%) and of diverse ethnicity and race (20% Black, 27% Asian). The median length of follow-up was 11.6 years (IQR 10.5-13.5) and median cumulative MMF exposure was 8.4 years (IQR 5.3-11.5) but 5.4 years (IQR 2.0-7.2) in the 5 patients who died.

At our unit, treatment regimens changed during the time period reviewed, moving to induction with MMF +/- Rituximab, mostly without oral steroids.

The MMF/MMF patients had lower uPCR and were less likely to have flared at 10 years f/up compared with the CyP/MMF group (Table 1 and Fig 1).

Importantly, no significant difference in adverse events was seen with MMF exposure ≥10yr vs <10yr (p=0.18) (Table 2).

Conclusions:

This is the largest study to report long-term outcomes in patients receiving MMF for both induction and maintenance treatment and the first to report data over ten years. Long-term treatment with MMF appears to be both effective and safe. These data support the use of non-CyP based regimens.